U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H15ClN6O
Molecular Weight 318.762
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BIIB021

SMILES

Cc1cnc(Cn2cnc3c(Cl)[nH]c(=N)nc32)c(C)c1OC

InChI

InChIKey=QULDDKSCVCJTPV-UHFFFAOYSA-N
InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)

HIDE SMILES / InChI

Molecular Formula C14H15ClN6O
Molecular Weight 318.762
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

BIIB021 binds in the ATP-binding pocket of Hsp90, interferes with Hsp90 chaperone function, and results in client protein degradation and tumor growth inhibition. Hsp90 is overexpressed in many types of cancer and acts to stabilize malignancy producing oncoproteins. Therefore, inhibition of Hsp90 with BIIB021 leads to the degradation of oncoproteins that drive malignancy.

Approval Year

PubMed

PubMed

TitleDatePubMed
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
2007 Jun 14
Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
2009 Aug 15
Patents

Sample Use Guides

In a phase II clinical trial, breast cancer patients were treated with either 100 mg twice daily + exemestane 25 mg once per day for 28 days, or 450 mg three times weekly + exemestane 25 mg once per day.
Route of Administration: Oral
BIIB021 was investigated as an inhibitor of heat shock protein 90 (Hsp90) alone and in combination with triptolide (TPL) on T-cell acute lymphoblastic leukemia. The cell viability of Human T-ALL cell line Molt-4 was measured using MTT assay. Molt-4 cells were treated with BIIB021 (50-800 nmol/L) which inhibited the cell growth in a dose-dependent manner. The IC50 value was 384.6 and 301.8 nmol/L, respectively, at 48 and 72 h.
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:38:26 UTC 2021
Edited
by admin
on Sat Jun 26 04:38:26 UTC 2021
Record UNII
851B9FQ7Q0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIIB021
Common Name English
CNF-2024
Common Name English
BIIB 021
Code English
BIIB 021 [WHO-DD]
Common Name English
CNF2024
Code English
BIIB-021
Code English
(6-CHLORO-9-(4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YLMETHYL)-9H-PURIN-2-YL)AMINE
Systematic Name English
9H-PURIN-2-AMINE, 6-CHLORO-9-((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)-
Systematic Name English
Code System Code Type Description
CAS
848695-25-0
Created by admin on Sat Jun 26 04:38:26 UTC 2021 , Edited by admin on Sat Jun 26 04:38:26 UTC 2021
PRIMARY
DRUG BANK
DB12359
Created by admin on Sat Jun 26 04:38:26 UTC 2021 , Edited by admin on Sat Jun 26 04:38:26 UTC 2021
PRIMARY
FDA UNII
851B9FQ7Q0
Created by admin on Sat Jun 26 04:38:26 UTC 2021 , Edited by admin on Sat Jun 26 04:38:26 UTC 2021
PRIMARY
PUBCHEM
16736529
Created by admin on Sat Jun 26 04:38:27 UTC 2021 , Edited by admin on Sat Jun 26 04:38:27 UTC 2021
PRIMARY
NCI_THESAURUS
C62517
Created by admin on Sat Jun 26 04:38:27 UTC 2021 , Edited by admin on Sat Jun 26 04:38:27 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE